Pep2Tango PTT-A Tetra-Agonist (GLP-1 + GIP + Amylin + Calcitonin) Produces 19% Weight Loss in DIO Rats vs 12% for Tirzepatide and CagriSema With Muscle Preservation
Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.